About this Research Topic
The success of immune checkpoint inhibitors (ICIs) across the organs demonstrates the existence of anti-cancer immunity in patients with malignant tumors. Breast cancer was traditionally thought to be poorly immunogenic compared to highly immunogenic (‘inflamed’) cancers, including malignant melanoma and non-small cell lung carcinoma. However, PD-1/ PD-L1 targeted therapies can improve the clinical outcomes of metastatic triple-negative breast cancer (TNBC) and anti-tumor response in early TNBC respectively.
As the efficacy of immuno-oncology (IO) monotherapy is limited, the development of IO is focused on the combination of ICIs and chemotherapy, targeted drugs, or radiation. However, the best partner for immune checkpoint inhibitors and optimal treatment sequence is still unknown. A precise understanding of immunobiology and the development of tumor-intrinsic and extrinsic biomarkers is required to maximize the clinical benefits of immunotherapy in patients with breast cancer.
In this Research Topic, we will focus on the basis of cancer immunity and current status, and future perspectives of IO for breast cancer. We welcome Mini-reviews, Reviews, and Original Articles for basic immunology and preclinical translational research in breast cancer.
As the efficacy of immuno-oncology (IO) monotherapy is limited, the development of IO is focused on the combination of ICIs and chemotherapy, targeted drugs, or radiation. However, the best partner for immune checkpoint inhibitors and optimal treatment sequence is still unknown. A precise understanding of immunobiology and the development of tumor-intrinsic and extrinsic biomarkers is required to maximize the clinical benefits of immunotherapy in patients with breast cancer.
In this Research Topic, we will focus on the basis of cancer immunity and current status, and future perspectives of IO for breast cancer. We welcome Mini-reviews, Reviews, and Original Articles for basic immunology and preclinical translational research in breast cancer.
Keywords: Breast cancer, tumor infiltrating lymphocyte, programmed death ligand-1, immune checkpoint inhibitor, biomarker
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
